background • Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all cancers in men and about (0.5-1) % of all breast cancers diagnosed each year. Although MBC was once associated with a considerably worse prognosis than in women, most contemporary reports of both male and female breast cancers do not substantiate a significantly worse prognosis in men. Due to the rarity of this tumor and the lack of information about it, this study was conducted to investigate the nature of the risk factors in MBC and compare them with female breast cancer (FBC). Materials and Methods • A retrospective case-control study at Al-Bairouni University hospital in Damascus. the study was performed on all patients with MBC diagnosed in Al-Bairouni hospital between 2007 and 2017, a total of 64 patients. then we selected 128 patients (2:1) identified as FBC from the same years of the study. the differences in prognostic factors were compared between cases and controls.

Results • MBC accounts for approximately 0.43% of all breast cancers. the mean age at diagnosis for men was 58 years compared with 50 years for women. the age ranges were (30-83) years for men and (25-79) years for women, MBCs were similar to FBCs in histological subtype, grade, tumor size, lymph node status and stage. the percentage of patients with metastatic disease is a little higher in men (21% for men, 17% for women). the majority of patients were positive for hormone receptors, slightly more among women. Patients with hER-2 positive were less in male patients (11% for men, 20% for women).

Conclusion • there are no significant differences between MBC and FBC. the difference between them is that men tend to be older than women at the time of diagnosis and there are less hER-2 positive patients in men.

Keywords : male breast cancer; men; MBC; female breast cancer; FBC; prognostic factors

Related Articles

reviews & ratings

0 reviews